Biologics
SineuGene Secures Dual U.S. and China IND Clearances for First-in-Class ALS Gene Therapy SNUG01
SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, anno...
August 18, 2025 | News
Superluminal Medicines and Eli Lilly Forge $1.3 Billion Collaboration on Undisclosed GPCR Targets in Cardiometabolic Disease and Obesity
Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as...
August 15, 2025 | News
Leads Biolabs Completes Patient Enrollment in World’s First Registrational Trial of Immunotherapy for Advanced EP-NEC
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced the successful completion of patient enrollment in t...
August 15, 2025 | News
Remegen’s Telitacicept Hits Phase III Milestone in Primary Sjögren’s Syndrome
Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endp...
August 14, 2025 | News
Shilpa Medicare Becomes World’s First to Gain Approval for NorUDCA, Pioneering Treatment for Over a Billion NAFLD Patients
NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage...
August 14, 2025 | News
WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...
August 13, 2025 | News
Mabwell Doses First U.S. Patient in Global Trial of Novel Nectin-4 ADC for Hard-to-Treat Triple-Negative Breast Cancer
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical stud...
August 13, 2025 | News
Sartorius Stedim Biotech Partners with Nanotein to Advance Immune Cell Manufacturing with NanoSpark® Reagents
Nanotein’s NanoSpark® reagents enhance cell activation and expansion in cell therapy manufacturing Exclusive global distribution agreement for...
August 12, 2025 | News
RemeGen Secures FDA Clearance for Phase II Trials of Innovative Bispecific Antibody RC148 in Advanced Solid Tumors
RemeGen Co., announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bisp...
August 11, 2025 | News
Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma
Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...
August 08, 2025 | News
Astria Licenses HAE Drug Navenibart to Japan’s Kaken in $32M+ Deal
-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties -- -- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart...
August 08, 2025 | News
Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors
Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...
August 06, 2025 | News
iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria
Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...
August 06, 2025 | News
METiS Technologies Secures RMB 400 Million in Series D Funding to Advance AI-Powered Nanodelivery and Accelerate CGT Innovation
METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series...
August 05, 2025 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
